Quick Answer
Calidi Biotherapeutics, Inc. reported R&D Expense of $9.74 million for fiscal year 2025.
Calidi Biotherapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $9.74M | +9.7% |
| 2024 | $8.88M | -31.7% |
| 2023 | $13.01M | +79.2% |
| 2022 | $7.26M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.36M | +9.7% | -8.9% |
| June 30, 2025 | $2.59M | +19.7% | +6.9% |
| March 31, 2025 | $2.42M | -11.6% | +12.6% |
| September 30, 2024 | $2.15M | -33.8% | -0.6% |
| June 30, 2024 | $2.17M | -31.8% | -21.0% |
| March 31, 2024 | $2.74M | +4.6% | -15.6% |
| September 30, 2023 | $3.25M | +67.1% | +2.3% |
| June 30, 2023 | $3.18M | — | +21.2% |
- Calidi Biotherapeutics, Inc. showed an increase of +9.7% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Calidi Biotherapeutics, Inc.’s r&d expense has grown by 34.2% (from $7.26 million to $9.74 million).
- The most recent figure is from Calidi Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: